BIOX-101 Data Will Be Presented at World Stroke Congress
The World Stroke Congress will feature late-breaking trial results for Bioxodes drug candidate BIOX-101 this October.
Updated on Sept. 24, 2026 in Stroke
Live Poll
Should development of novel treatments for currently untreatable medical conditions like stroke be prioritized by industry?
The World Stroke Congress in Seoul will present final Phase 2a BIRCH trial data for the stroke drug candidate BIOX-101 on October 21, 2026. This trial evaluates the drug for patients suffering from spontaneous acute intracerebral hemorrhage.
Why it matters
There is currently no approved medical treatment for acute intracerebral hemorrhage, making the potential development of a therapeutic agent a significant milestone for stroke care. Bioxodes is positioning these results to support a larger Phase 2b clinical trial.
The BIRCH trial enrolled 23 patients with hemorrhages measuring 5 to 60 mL, comparing a 48-hour intravenous infusion of BIOX-101 initiated within 24 hours of symptom onset against standard care alone. Final functional outcomes were tracked through Day 360.
The players
Bioxodes
Bioxodes is a Belgian biopharmaceutical company based in Gosselies that specializes in developing therapies for stroke and other vascular conditions.
World Stroke Congress
The World Stroke Congress is an international scientific event organized by the World Stroke Organization to discuss the latest advancements in stroke research and clinical practice.
The details
The upcoming presentation at the 18th World Stroke Congress highlights the study conducted across 8 units in Belgium. Following the data reveal, Bioxodes intends to host an event for key opinion leaders and an investor webcast.
Timeline
May 2026: Topline data for the BIRCH trial were reported.
September 24, 2026: The late-breaking presentation selection was announced.
October 21, 2026: The final dataset will be presented at the World Stroke Congress.
October 21-23, 2026: The 18th World Stroke Congress takes place in Seoul.
Day 360: Functional outcomes were measured for trial patients.
The Big Picture
The 18th World Stroke Congress serves as a critical venue where clinical trial progress is measured against global benchmarks for patient outcomes in stroke treatment. This presentation follows the standard pattern of using international medical congresses to release pivotal data for experimental drug candidates.
Currently, no approved therapies exist for patients suffering from acute intracerebral hemorrhage, meaning these trial developments are critical to potentially establishing a new standard of care. Successful clinical results could eventually lead to the first available medical intervention for this specific stroke type.
The takeaway
The upcoming presentation in Seoul provides an essential look at a potential treatment for a currently unaddressed medical emergency. Clinicians and researchers will closely examine the Day 360 functional outcome data to determine if the drug warrants further large-scale investment.
What happens next
Bioxodes is preparing for a Phase 2b BIRCH 2 trial that will involve approximately 200 patients, pending further discussions with investors and partners.
Further reading
For more information on current treatment landscapes, visit the Stroke section.
Live Poll
Should development of novel treatments for currently untreatable medical conditions like stroke be prioritized by industry?
